EDSS and disease duration associate with progression independent of relapse and MRI activity in natalizumab-treated multiple sclerosis patients

20260 citationsJournal Articlehybrid Open Access

Authors

Puthenparampil Marco · University of Padua

Passamonti Margherita · University of Padua

Rozzi Martina · University of Padua

Basili Elisa · University of Padua

Mauceri Valentina Annamaria · University of Padua

Nosadini Margherita · Città della Speranza Foundation

Sartori Stefano ·

Abstract

PIRMA was identified as the main driver of disability progression in RRMS treated with NTZ and is predicted by disease duration and EDSS at therapy initiation.

Topics & Keywords

Multiple Sclerosis Research Studies Polyomavirus and related diseases Multiple Myeloma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Multiple Sclerosis and Related Disorders

Volume 109, pp. 107148-107148

DOI: 10.1016/j.msard.2026.107148

Field-Weighted Citation Impact: 0.00